BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 28987602)

  • 1. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
    Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
    Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
    Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
    Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
    Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y
    Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
    Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
    Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
    Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
    Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.
    Milelli A; Marchetti C; Turrini E; Catanzaro E; Mazzone R; Tomaselli D; Fimognari C; Tumiatti V; Minarini A
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1001-1004. PubMed ID: 29496367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
    Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
    Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.
    Benelkebir H; Hodgkinson C; Duriez PJ; Hayden AL; Bulleid RA; Crabb SJ; Packham G; Ganesan A
    Bioorg Med Chem; 2011 Jun; 19(12):3709-16. PubMed ID: 21382717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
    Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
    Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
    Fioravanti R; Romanelli A; Mautone N; Di Bello E; Rovere A; Corinti D; Zwergel C; Valente S; Rotili D; Botrugno OA; Dessanti P; Vultaggio S; Vianello P; Cappa A; Binda C; Mattevi A; Minucci S; Mercurio C; Varasi M; Mai A
    ChemMedChem; 2020 Apr; 15(7):643-658. PubMed ID: 32003940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
    Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
    J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Tranylcypromine/Hydroxylcinnamic Acid Hybrids as Lysine-Specific Demethylase 1 Inhibitors with Potent Antitumor Activity.
    Han Y; Wu C; Lv H; Liu N; Deng H
    Chem Pharm Bull (Tokyo); 2015; 63(11):882-9. PubMed ID: 26521853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR Modeling, Molecular Docking and Molecular Dynamics Simulations Studies of Lysine-Specific Demethylase 1 (LSD1) Inhibitors as Anticancer Agents.
    Abdizadeh R; Heidarian E; Hadizadeh F; Abdizadeh T
    Anticancer Agents Med Chem; 2021; 21(8):987-1018. PubMed ID: 32698753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
    Sun Q; Ding D; Liu X; Guo SW
    Reprod Biol Endocrinol; 2016 Apr; 14():17. PubMed ID: 27062244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
    Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
    Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.